RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
  AIDS
  Anthrax
  Dengue
  Ebola
  HCV
  Influenza
  Leishmaniasis
  Malaria
  MRSA
  Mumps
  Pertussis
  Prion Diseases
  SARS
  Shigella
  Small Pox
  Tuberculosis
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Leishmaniasis Channel

subscribe to Leishmaniasis newsletter
Latest Research : Infectious Diseases : Leishmaniasis

   EMAIL   |   PRINT
Vaccine developed to fight black fever

Apr 25, 2006 - 8:38:00 PM , Reviewed by: Priya Saxena
The Swiss team is now moving on towards testing the vaccine on animals.

 
[RxPG] Swiss scientists have developed a vaccine that could protect animals and humans from Leishmaniasis, or black fever, a parasitic disease that kills about 60,000 people a year.

Leishmaniasis, spread by the bite of the sandfly, attacks the spleen, bone marrow and liver and destroys the immune system. Untreated, it is nearly always fatal.

No vaccine yet exists for the disease that affects 500,000 people worldwide each year - mostly in India, Bangladesh, Nepal, Sudan and Brazil.

The vaccine, designed by researchers at the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH), Zurich, uses synthetic forms of carbohydrates taken from the parasite or bacteria responsible for the disease.

Laboratory studies have shown that the possible vaccine designed by the team produces a protective action against Leishmaniasis, stimulating the patient's own immune system, reported the online edition of BBC News.

The Swiss team is now moving on towards testing the vaccine on animals.

However, they say the vaccine development is in an early stage. Animal tests will take two years and pre-clinical trials another two to three years. A final vaccine is at least five years off, one researcher said.

Among common symptoms of the disease are lesions on the skin, persistent fever, night sweats, fatigue, weakness, appetite loss, vomiting and diarrhoea in children and cough.

There are about half a million new cases of visceral Leishmaniasis occurring each year.

The disease currently does not have any effective treatment. The most common drugs used to treat the disease have serious side effects and are expensive.



Publication: Indo-Asian News Service

Advertise in this space for $10 per month. Contact us today.


Related Leishmaniasis News
Vaccine developed to fight black fever
Potential vaccine developed for deadly leishmaniasis disease
Drug-Resistant Leishmania tropica Parasites Detected in Iranian Cutaneous Leishmaniasis

Subscribe to Leishmaniasis Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)